Sigilon Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000155837023013494 Filed on August 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $19.62M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $44.87M
YoY Change -51.32%
LONG-TERM ASSETS
Property, Plant & Equipment $2.589M
YoY Change -23.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $10.69M
YoY Change -29.88%
TOTAL ASSETS
Total Short-Term Assets $44.87M
Total Long-Term Assets $10.69M
Total Assets $55.56M
YoY Change -48.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.110M
YoY Change 5.61%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.25M
YoY Change -24.23%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $25.25M
Total Long-Term Liabilities
Total Liabilities $28.11M
YoY Change -49.45%
SHAREHOLDERS EQUITY
Retained Earnings -$271.7M
YoY Change 12.55%
Common Stock $3.000K
YoY Change -90.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.45M
YoY Change
Total Liabilities & Shareholders Equity $55.56M
YoY Change -48.28%

Cashflow Statement

Concept 2023 Q3 2023 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.00
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.76
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.32
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2501900
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2492251
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2499701
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2490779
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2501900
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2492251
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2499701
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2490779
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.00
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.32
dei Entity Central Index Key
EntityCentralIndexKey
0001821323
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2497429
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2502084
CY2023Q2 sgtx Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Sigilon Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity File Number
EntityFileNumber
001-39746
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4005543
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Binney Street, Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
336-7540
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
SGTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2514498
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19621000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42066000
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
15279000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
27560000
CY2023Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
4495000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
2171000
CY2023Q2 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
2363000
CY2022Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
1287000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2860000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1077000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
250000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
250000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
44868000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
74411000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2589000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2854000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7062000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8979000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1040000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1034000
CY2023Q2 us-gaap Assets
Assets
55559000
CY2022Q4 us-gaap Assets
Assets
87278000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1110000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
936000
CY2023Q2 sgtx Accrued Expenses And Other Current Liabilities Current
AccruedExpensesAndOtherCurrentLiabilitiesCurrent
5835000
CY2022Q4 sgtx Accrued Expenses And Other Current Liabilities Current
AccruedExpensesAndOtherCurrentLiabilitiesCurrent
6021000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4523000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4485000
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
6667000
CY2023Q2 sgtx Deferred Revenue Related Party Current
DeferredRevenueRelatedPartyCurrent
13779000
CY2022Q4 sgtx Deferred Revenue Related Party Current
DeferredRevenueRelatedPartyCurrent
12885000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
25247000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
30994000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2865000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4888000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12021000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
233000
CY2023Q2 us-gaap Liabilities
Liabilities
28112000
CY2022Q4 us-gaap Liabilities
Liabilities
48136000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2502084
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2497429
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
299305000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
296368000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-177000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-429000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-271684000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-256800000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
27447000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
39142000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55559000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87278000
CY2023Q2 us-gaap Revenues
Revenues
5900000
CY2022Q2 us-gaap Revenues
Revenues
2883000
us-gaap Revenues
Revenues
10758000
us-gaap Revenues
Revenues
6048000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7451000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11877000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15233000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23495000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5884000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5042000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10207000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10066000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
13335000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
16919000
us-gaap Operating Expenses
OperatingExpenses
25440000
us-gaap Operating Expenses
OperatingExpenses
33561000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7435000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14036000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14682000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27513000
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
433000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
178000
us-gaap Interest And Other Income
InterestAndOtherIncome
909000
us-gaap Interest And Other Income
InterestAndOtherIncome
242000
CY2023Q2 us-gaap Interest Expense
InterestExpense
310000
CY2022Q2 us-gaap Interest Expense
InterestExpense
543000
us-gaap Interest Expense
InterestExpense
921000
us-gaap Interest Expense
InterestExpense
1034000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
81000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
55000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
85000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
100000
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-275000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-275000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-71000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-310000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-202000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-692000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7506000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14346000
us-gaap Net Income Loss
NetIncomeLoss
-14884000
us-gaap Net Income Loss
NetIncomeLoss
-28205000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.00
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.32
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2501900
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2492251
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2499701
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2490779
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
96000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-167000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
252000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-546000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
96000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-167000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
252000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-546000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7410000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14513000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14632000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28751000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
39142000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
25000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1349000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
156000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7378000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
48000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
33294000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1559000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
96000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7506000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
27447000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
77160000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
47000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1618000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-379000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13859000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
64588000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1731000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-167000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14346000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
51806000
us-gaap Profit Loss
ProfitLoss
-14884000
us-gaap Profit Loss
ProfitLoss
-28205000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
625000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
633000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
10000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
20000
us-gaap Share Based Compensation
ShareBasedCompensation
2908000
us-gaap Share Based Compensation
ShareBasedCompensation
3349000
sgtx Noncash Lease Expense
NoncashLeaseExpense
1917000
sgtx Noncash Lease Expense
NoncashLeaseExpense
2114000
sgtx Noncash Interest Expense
NoncashInterestExpense
77000
sgtx Noncash Interest Expense
NoncashInterestExpense
140000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-275000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
39000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-45000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2324000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-36000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
1076000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1782000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
873000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
205000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1095000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-126000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2374000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-233000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
281000
sgtx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1985000
sgtx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-2256000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
894000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6044000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15558000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34269000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
6892000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
41040000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
19464000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
490000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
506000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
169000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12130000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38377000
us-gaap Repayments Of Debt
RepaymentsOfDebt
19040000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
29000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
48000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-19011000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22439000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-72598000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43350000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108511000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20911000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35913000
us-gaap Interest Paid Net
InterestPaidNet
841000
us-gaap Interest Paid Net
InterestPaidNet
888000
sgtx Gain On Trade In Of Fixed Assets On Noncash Investing And Financing Activities
GainOnTradeInOfFixedAssetsOnNoncashInvestingAndFinancingActivities
40000
us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
1000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
21000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
5000
sgtx Lease Assets Obtained In Exchange For Lease Liabilities
LeaseAssetsObtainedInExchangeForLeaseLiabilities
68000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7500000
us-gaap Net Income Loss
NetIncomeLoss
-14900000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-43600000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-271700000
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
34900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, research and development expenses and stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</p>
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2842000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Concentration of Credit Risk and of Significant Suppliers</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The financial instruments that potentially subject the Company to concentrations of credit risk are cash and accounts receivable. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. As of June 30, 2023 and December 31, 2022, 100% of the Company’s receivables were related to the Company’s collaboration agreements with Eli Lilly and Company (Note 8). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is dependent on third-party manufacturers to supply certain products for research and development activities in its programs. The Company currently has a supplier of certain raw materials that would be considered a sole supplier. If the Company cannot access additional suppliers or secure sufficient inventory of these raw materials, its programs could be adversely affected by an interruption in the availability of these raw materials.</p>
CY2023Q2 sgtx Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
15455000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
176000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
15279000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
27984000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
424000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
27560000
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
7436000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
23231000
CY2023Q2 sgtx Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Two
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo
7843000
CY2022Q4 sgtx Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Two
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo
4329000
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
15279000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
27560000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4243000
CY2023Q2 sgtx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
585000
CY2022Q4 sgtx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
817000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2379000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
714000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
195000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7162000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7176000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4573000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4322000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2589000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2854000
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
600000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
600000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
52000
CY2023Q2 sgtx Accrued Expenses And Other Current Liabilities Current
AccruedExpensesAndOtherCurrentLiabilitiesCurrent
5835000
CY2022Q4 sgtx Accrued Expenses And Other Current Liabilities Current
AccruedExpensesAndOtherCurrentLiabilitiesCurrent
6021000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
18333000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
6667000
CY2022Q4 sgtx Long Term Debt Net Of Current Portion Including Debt Discount
LongTermDebtNetOfCurrentPortionIncludingDebtDiscount
11666000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
700000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
345000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12021000
CY2023Q2 sgtx Number Of Equity Compensation Plans
NumberOfEquityCompensationPlans
2
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
377749
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
86.19
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
140529
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
24323
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
47.96
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
188
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
19.24
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
493767
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
67.53
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1752000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
214592
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
91.88
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
269000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3600000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.18
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.88
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
108.55
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1559000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1731000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2908000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3349000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7506000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14346000
us-gaap Net Income Loss
NetIncomeLoss
-14884000
us-gaap Net Income Loss
NetIncomeLoss
-28205000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7506000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14346000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14884000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28205000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2501900
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2492251
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2499701
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2490779
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.00
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.76
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.32
CY2023Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1464
CY2022Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1464
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1464
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1464
CY2023Q2 sgtx Incremental Common Shares Attributable To Unvested Restricted Stock
IncrementalCommonSharesAttributableToUnvestedRestrictedStock
11083
CY2022Q3 sgtx Incremental Common Shares Attributable To Unvested Restricted Stock
IncrementalCommonSharesAttributableToUnvestedRestrictedStock
15223
sgtx Incremental Common Shares Attributable To Unvested Restricted Stock
IncrementalCommonSharesAttributableToUnvestedRestrictedStock
11083
sgtx Incremental Common Shares Attributable To Unvested Restricted Stock
IncrementalCommonSharesAttributableToUnvestedRestrictedStock
17069
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
493767
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
386957
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
493767
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
312157
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
506314
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
403644
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
506314
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
330690

Files In Submission

Name View Source Status
0001558370-23-013494-index-headers.html Edgar Link pending
0001558370-23-013494-index.html Edgar Link pending
0001558370-23-013494.txt Edgar Link pending
0001558370-23-013494-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgtx-20230630.xsd Edgar Link pending
sgtx-20230630x10q.htm Edgar Link pending
sgtx-20230630xex10d1.htm Edgar Link pending
sgtx-20230630xex10d2.htm Edgar Link pending
sgtx-20230630xex10d3.htm Edgar Link pending
sgtx-20230630xex10d4.htm Edgar Link pending
sgtx-20230630xex31d1.htm Edgar Link pending
sgtx-20230630xex31d2.htm Edgar Link pending
sgtx-20230630xex32d1.htm Edgar Link pending
Show.js Edgar Link pending
sgtx-20230630_lab.xml Edgar Link unprocessable
sgtx-20230630_pre.xml Edgar Link unprocessable
sgtx-20230630x10q_htm.xml Edgar Link completed
sgtx-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
sgtx-20230630_def.xml Edgar Link unprocessable